XenoPort: Biogen’s Little Brother And More – Seeking Alpha

by admin on January 18, 2013

XenoPort: Biogen's Little Brother And More
Seeking Alpha
Horizant (gabapentin enacarbil) is XenoPort's treatment for restless leg syndrome (RLS), approved in the U.S. in April 2011 and in Japan in January 2012. Horizant has gone through a turbulent period since receiving approval from the FDA, but XenoPort

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: